Despite significant advances in the treatment of cervical, ovarian, and uterine cancers with
the approvals of checkpoint and PARP inhibitors into standard treatment, patients with …

Simple Summary Endometrial cancer has a high epidemiological impact, and its
management is part of everyday clinical practice. International guidelines have been …

Background Risk-assessment of endometrial cancer (EC) is based on clinicopathological
factors and molecular subgroup. It is unclear whether adding hormone receptor expression …

PURPOSE Immunotherapy and chemotherapy combinations have shown activity in
endometrial cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than …

PURPOSE The molecular classification of endometrial cancer (EC) has proven to have
prognostic value and is predictive of response to adjuvant chemotherapy. Here, we …

Predicting distant recurrence of endometrial cancer (EC) is crucial for personalized adjuvant
treatment. The current gold standard of combined pathological and molecular profiling is …

Abstract Background Recently, the new 2023 International Federation of Gynecology and
Obstetrics (FIGO) staging system for endometrial cancer (EC) critically integrating new …

Purpose: The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage
I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review …

As data-driven science, artificial intelligence (AI) has paved a promising path toward an
evolving health system teeming with thrilling opportunities for precision oncology …

The treatment for endometrial cancer is rapidly evolving with the development of molecular
analysis and novel strategies. Surgical resection, cytotoxic chemotherapy, endocrine or …